BIND Therapeutics and Amgen Amend Collaboration Agreement for Kinase Inhibitor Nanomedicine

  BIND Therapeutics and Amgen Amend Collaboration Agreement for Kinase
  Inhibitor Nanomedicine

                 Extends Option Exercise Period by Six Months

Business Wire

CAMBRIDGE, Mass. -- December 12, 2013

BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform
company developing targeted and programmable therapeutics called Accurins™,
announced today that it has amended its development and commercialization
collaboration agreement with Amgen Inc. to extend the period during which
Amgen may exercise its option by six months. BIND entered into a global
collaboration agreement with Amgen on January 7, 2013 to develop and
commercialize a kinase inhibitor nanomedicine for treating a range of solid
tumors based on BIND’s platform for targeted and programmable nanomedicines
and Amgen’s undisclosed proprietary kinase inhibitor. Under the agreement,
Amgen had twelve months from the effective date to exercise its option to
select a novel Accurin candidate for further development. The option period
under the amended collaboration agreement has been extended to July 7, 2014 to
allow for completion of the research plan. None of the other terms of the
original agreement have been changed.

Amgen has the exclusive right to pursue development and commercialization of
an Accurin kinase inhibitor against solid tumor targets to be selected by
Amgen. Both companies are working together on preclinical development and
agreed that Amgen would assume responsibility for any future development and
commercialization. BIND is eligible to receive up-front and development
milestone payments totaling $46.5 million, up to an additional $134 million in
regulatory and sales milestone payments for the first therapeutic indication
and additional payments for target exclusivity. BIND will receive tiered
royalties on potential future sales.

About BIND Therapeutics

BIND Therapeutics is a clinical-stage nanomedicine platform company developing
Accurins, its novel targeted therapeutics. BIND intends to leverage its
Medicinal Nanoengineering^® platform to develop a pipeline of Accurins,
initially in oncology, as well as Accurins in collaboration with
biopharmaceutical companies. BIND’s lead drug candidate, BIND-014, is an
Accurin that targets PSMA and contains docetaxel, a clinically-validated and
widely used cancer chemotherapy drug. BIND-014 is currently in Phase 2
clinical trials for non-small cell lung cancer and metastatic
castrate-resistant prostate cancer. BIND has announced collaborations with
Amgen Inc., Pfizer Inc. and AstraZeneca AB to develop Accurins based on
therapeutic payloads from their product pipelines. BIND’s platform originated
from the pioneering nanotechnology research at the Massachusetts Institute of
Technology and Brigham and Women’s Hospital/Harvard Medical School of BIND’s
scientific founders and directors Dr. Robert Langer and Dr. Omid Farokhzad.
For more information, please visit the company's web site at

Forward-Looking Statements Disclaimer

This press release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995. All statements contained
in this press release that do not relate to matters of historical fact should
be considered forward-looking statements, including without limitation
statements regarding the payments that could be received under a collaboration
agreement, the potential for the company’s platform, and the reach of our
medicinal nanoengineering platform..

These forward-looking statements are based on management’s current
expectations. These statements are neither promises nor guarantees, but
involve known and unknown risks, uncertainties and other important factors
that may cause our actual results, performance or achievements to be
materially different from any future results, performance or achievements
expressed or implied by the forward-looking statements, including, but not
limited to, the following: our limited operating history and expectation of
losses for the foreseeable future; our need for additional funding;
uncertainties regarding our development efforts and the outcomes of studies of
our products; our reliance on collaborations with other biopharmaceutical
companies to develop Accurins based on therapeutic payloads from their current
pipelines; our complete reliance on third-party manufacturers and third
parties to conduct all our clinical trials and manufacture of drug candidates;
our inability to obtain regulatory approval for our existing or future product
candidates; unanticipated safety or efficacy concerns; the failure of our drug
candidates to achieve market success; our inability to obtain or enforce
patent protection for our products; our inability to establish effective
sales, marketing and distribution capabilities; our failure to comply with
regulatory requirements; the ability of our officers, directors and principal
stockholders to control matters submitted to stockholders for approval; and
these and the other important factors discussed under the caption "Risk
Factors" in our quarterly report on Form 10-Q filed with the Securities and
Exchange Commission, or SEC, on November 5, 2013, and our other reports filed
with the SEC. These factors could cause actual results to differ materially
from those indicated by the forward-looking statements made in this press
release. Any such forward-looking statements represent management's estimates
as of the date of this press release. While we may elect to update such
forward-looking statements at some point in the future, we disclaim any
obligation to do so, even if subsequent events cause our views to change.
These forward-looking statements should not be relied upon as representing our
views as of any date subsequent to the date of this press release.


The Yates Network
Gina Nugent, 617-460-3579
Press spacebar to pause and continue. Press esc to stop.